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Abstract 
Selective PCR amplification of human and mouse genomic DNAs with oligonucleotides encoding highly conserved regions of the S-opioid and 
somatostatin receptors generated a human DNA probe (hOPO1, 761 bp) and its murine counterpart (mOP86, 447 bp). hOPO1 was used to screen 
a cDNA library from human brainstem. A clone (named hORL1) was isolated, sequenced and found to encode a protein of 370 amino acids whose 
primary structure displays the seven putative membrane-spanning domains of a G protein-coupled membrane receptor. The hORL1 receptor is most 
closely related to opioid receptors not only on structural (sequence) but also on functional grounds: hORL1 is 49-50% identical to the murine ,u-, 
6- and rc-opioid receptors and, in CHO-Kl cells stably transfected with a pRc/CMV:hORLl construct, ORLl mediates inhibition of adenylyl cyclase 
by etorphine, a ‘universal’ (nonselective) opiate agonist. Yet, hORL1 appears not to be a typical opioid receptor. Neither is it a somatostatin or o 
(N-allylnormetazocine) receptor. mRNAs hybridizing with synthetic oligonucleotides complementary to mOP86 are present in many regions of the 
mouse brain and spinal cord, particularly in limbic (amygdala, hippocampus, septum, habenula, .. .) and hypothalamic structures. We conclude that 
the hORL1 receptor is a new member of the opioid receptor family with a potential role in modulating a number of brain functions, including 
instinctive behaviours and emotions. 
Key w~ora!s: G protein-coupled membrane receptor; Etorphine; Diprenorphine; Cyclic AMP; Hybridization, in situ; Brain; Spinal 
cord 
1. Introduction 
Opioid substances act in the central (CNS) and periph- 
eral nervous systems to produce numerous pharmaco- 
logical effects which are conveniently classified as ‘acute’ 
and ‘chronic’. The acute effects of opioids (analgesia, 
respiratory depression, miosis, constipation, . . ., sensa- 
tion of well-being) appear to be of neuromodulatory 
origin and may reflect in most if not all cases, presynaptic 
depression of neurotransmitter release as examplified by 
the one of substance P in relation with spinal analgesia 
[ 11. As for the chronic effects (tolerance and dependence), 
they may reflect neuronal adaptative changes analogous 
to those seen in cell learning and memory [2]. In practice, 
*Corresponding author. Fax: (33) 6117-5994. 
Abbreviations: CNS, central nervous system; G protein, guanine nucle- 
otide-binding regulatory protein; GPCR, G protein-coupled membrane 
receptor; ORLl, opioid receptor-like receptor or cDNA; TMS, trans- 
membrane segment. 
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the unwanted effects of opioids delicate their widespread 
use as therapeutic agents and makes them a major class 
of abused drugs. 
At the molecular level, opioids act primarily via three 
major types, p, 6 and K of specific membrane receptors 
which display clear in vitro binding preference for mor- 
phine, enkephalins and benzomorphans, respectively [3]. 
These receptors couple with pertussis toxin-sensitive, 
guanine nucleotide-binding regulatory proteins (G pro- 
teins) either to inhibit adenylyl cyclase [4] and/or calcium 
channels [5] or to stimulate potassium channels [6]. 
The cDNAs of the 6- [7,8], p- [9-l l] and IC- [12-U] 
opioid receptors have recently been cloned and found to 
encode monomeric proteins having the structure of G 
protein-coupled membrane receptors (GPCRs). Since it 
was initially noticed [8] that the 6-opioid receptor, the 
first to have been cloned, resembles omatostatin recep- 
tors, we applied the PCR amplification strategy of Libert 
et al. [16] to clone new members of the opioid receptor 
family. Selective PCR amplification of human genomic 
DNA with oligonucleotides encoding highly conserved 
regions of the &opioid and somatostatin receptors gen- 
All rights reserved. 
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erated a DNA probe of 761 bp which we used to screen 
a cDNA library from human brainstem. Here, we report 
the isolation of a cDNA clone encoding hORL1 (human 
@ioid Receptor-Like l), a protein of 370 amino acids 
whose &imary structure is also typically that of a 
GPCR. The hORL1 receptor exhibits substantial se- 
quence identities with opioid receptors and, once stably 
transfected into CHO-Kl cells, mediates inhibition of 
adenylyl cyclase by etorphine, a nonselective opiate ag- 
onist. ORLl transcripts are expressed in many regions 
of the mouse CNS, especially in the limbic areas, hypo- 
thalamus, brainstem and spinal cord. 
2. Experimental procedures 
2.1. DNA probe, cDNA library and library screening 
Human, mouse and rat genomic DNAs were subjected to low-strin- 
gency PCR amplification using pairs of degenerate, synthetic oligonu- 
cleotides corresponding to consensus equences of the second (forward 
priming) and sixth or seventh (reverse priming) membrane-spanning 
domains of the mouse S-opioid and somatostatin receptors. The ampli- 
fication products were cloned into phage Ml3 and sequenced. One 
human product (hOPO1,761 bp long; see Fig. 1) was found, except for 
a short medial intron of 118 bp, to encode a sequence of 207 amino acids 
displaying 57.5% identity with the homologous domain of the bopioid 
receptor. Likewise, one murine product (mOP86, 447 bp long) also 
contained a very short (77 bp) putative intron and encoded the same 
amino acid sequence as did hOPO1, indicating that the human and 
murine probes corresponded to species variants of the same gene. 
hOPO1 was r2P-labeled with Boehringer’s appropriate kit and used to 
screen a sized (2-7 kb) cDNA library from human brainstem in Phar- 
macia’s pTZ18R phagemid. Twelve x 30,000 recombinant bacterial 
colonies were tested, in-duplicate, by overnight incubation at 42°C with 
“P-labeled hOPO1 (500.000 cnm/ml) in hvbridization buffer (0.25% , . , I 
nonfat dried milk, Regilait; 0.5% SDS; 5 mM EDTA; 40% formamide 
and 6 x SW) followed by two 20-min washes with 2 x SSC/O. 1% SDS 
at 60°C and one 30-min wash with 0.1 x SSC/O.l% SDS at 42°C. Au- 
toradiographic analysis of the filters revealed a single positive clone, 
hereafter designated hORL1 which, upon a second round of screening 
as above, was isolated. 
2.2. Sequencing 
Sequencing on both strands of cDNA insert hORL1 was performed 
by the dideoxynucleotide chain termination method [17] after partial 
subcloning in M 13mp derivatives, u ing an automated DNA sequencer 
(Applied Biosystems 370A). 
2.3. Expression in cell lines 
A HindIII-Pstl fragment of 1,953 bp containing the entire coding 
region of hORL1 was subcloned in plasmids pSVL (Pharmacia) and 
pRc/CMV (Invitrogen). pSVL : hOLR 1 was used to transfect COS-7 
cells and pRc/CMV: hOLR1 to transform CHO-Kl cells. CO97 cells 
were grown to 5 50% confluency in 60 mm dishes in Dulbecco’s mod- 
ified Eagle medium (Gibco) and transfected with 2-5 pg/dish of 
pSVL: hOLR1 by the method using DEAE-dextran and 
chloroquine [18]. 72 h later, the cells were rinsed with phosphate-buff- 
ered saline, scraped off their matrix into Tris-HCl buffer (50 mM, pH 
7.4) and processed as otherwise described [19] to yield a crude mem- 
brane fraction. The COS cells membranes were examined for expression 
of binding activity with radioactive ligands by the method of rapid 
filtration on glass fiber disks. The radiolabeled ligands were: [15,16(n)- 
‘H]diprenorphine and [15,16-3H]etorphine (Amersham), [‘Z51@-endor- 
phin (NEN), ‘251-Labeled somatostatin-14 and SMS 201-995 (gifts from 
Dr. Ch. Susini, INSERM, Toulouse), [5-‘H]DTG (NEN) and [3H]JO- 
1784 (Jouveinal Laboratories, Fresnes). CHO-KZ cells grown to near 
confluency in 60 mm dishes in Ham’s F12 medium (G&co) were trans- 
fected with 5 &dish of pRc/CMV: hOLR1 by a modified calcium 
phosphate precipitate method [20]. 24 h after transfection, the cells were 
treated with trypsin and diluted 1: 10. The following day, selection of 
transfectants was initiated by addition of 400 fig/ml G418 (Gibco). 
Fifteen days later, individual resistant clones were isolated, cultured 
separately and checked for the presence of hORL1 transcripts by 
Northern blotting. These cells were used to screen a number of unla- 
beled ligands for ability to increase basal or decrease forskolin-induced 
intracellular CAMP. Cyclic AMP levels were assayed for in aliquots of 
2 x 10’ cells pre-incubated for 1 h at 37°C with 0.6pCi [‘Hladenine (23 
Cilmmol, Amersham) in Ham’s F12. Stimulation of CAMP production 
was for 10 min at 37°C in 0.2 ml HEPES buffered Krebs-Ringer saline 
with 10 ,uM forskolin in the presence of 0.1 mM IBMX (Sigma) and 
0.1 mM Ro-20, 1724 (Biomol Res.). The reaction was stopped by 
addition of 20 ,~l 2.2 N HCl and CAMP was isolated by the single 
column procedure of Alvarez and Daniels [21]. 
2.4. In situ hybridization 
Coronal sections 15 pm thick from frozen mouse brain and spinal 
cord were thaw-mounted onto poly-L-lysine coated slides, fixed with 
paraformaldehyde and examined for in situ hybridization as previously 
described [22] with the oligonucleotides: 
5’-GTGCCCTGGAAGGGCAGTGTCAGCAAGACCAGGGTATC- 
AGCCAGT-3 
5’-GATAGCAATGACCGTCTTGCACAGTGCATTCCCAAATGG- 
CCAGAA-3 
complementary to mOP86,,, and mOP86,,_,,,, respectively. The two 
45-mers were synthesized on an Applied Biosystems 381A DNA synthe- 
sizer. They were mixed in a 1: 1 ratio and radiolabeled with [o-“S]- 
dATP to t 1,000 Ci/mmol at their 3’ end with terminal deoxynucleoti- 
dyltransferase. Nonspecific hybridization was assessed for with ol- 
igonucleotides of same length, G-C content and specific radioactivity 
but complementary to unrelated mRNAs. Hybridization of the sections 
with the labeled probes and a loo-fold excess of cold probes or unre- 
lated probes as well as pretreatment of the sections with RNAse (20 
pug/ml) were also performed. 
3. Results 
Fig. 1 shows part of the nucleotide sequence of the 
hORL1 insert (3.2-3.3 kb) with a long open reading 
frame of 1,110 bases encoding a protein of 370 amino 
acids (M, 40,690). Fig. 1 also shows, for comparison, the 
partial sequences obtained by PCR from mouse 
(mOP86) and rat (rOP19) genomic DNA. ORLl appears 
to be highly conserved in mammalian species: along the 
366 nucleotide overlap between the human and mouse 
coding sequences, each interrupted by a short intron, the 
identity amounts to 87%. When comparing the amino 
acid sequences, the identity increases to 99%, with a 
single substitution in 123 amino acids. The hORL1 pro- 
tein contains the seven stretches of predominantly hydro- 
phobic amino acid residues which are thought to repre- 
sent membrane-spanning domains [23-251. As opioid re- 
ceptors and most GPCRs do, hORL1 displays many 
putative consensus ites for post-translational modifica- 
tions. These include: (i) three asparagine residues within 
Asn-X-Ser motifs for N-linked glycosylation near its 
NH,-terminus; (ii) a pair of conserved cysteine residues 
which may connect exofacial loops 1 (ClzJ and 2 (C,,) 
by a disulfide bridge [26,27]; and (iii) putative palmitoyl- 
ation sites (&, C,,, and &) downstream of trans- 
membrane segment (TMS) 7 [28,29]. All cytoplasmic do- 
mains contain a number of serine and threonine residues 
representing potential sites of phosphorylation, a process 
which is known to be involved in homologous and/or 
35 
Fig. 1. Nucleotide sequence of ORLl receptor cDNA. The partial nucleotide sequence of the human cDNA (h0RU) encoding the ORLl receptor 
and the deduced amino acid sequence (hORL1) are represented. The sequence of the genomic fragment amplified by low stringency PCR and used 
as probe (hOWI) is aligned, showing the location of the short intervening sequence (lowercase characters), as well as PCR-generated genomic 
sequences from mouse (mOP86) and rat (rOPl9). Identities with the human cDNA @O&Y) are represented by dots. The base substitutions in the 
mouse and rat sequences do not change the amino acid sequence, with the exception of the G4,6 in the mouse sequence that changes a threonine into 
an alanine. The putative glycosylation (Asn) and palmitoylation (Cys) sites are underlined once and twice, respectively. The potential sites for 
phosphorylation by proteine kinases A (R/K,R/K,X,S/T) and C (SfT,X,R/K) are indicated by open and closed triangles, respectively. The dashed 
lines below the hORL1 amino acid sequence situate the membrane-spanning domains, numbered I-VII. 
heterologous desensitization of the /?,-adrenergic and 
other GPCRs [30,31]. 
Fig. 2 shows that hORL1 is related to somatostatin 
and, most closely so (see dendrogram), to opioid recep- 
tors. Similar amino acid residues in hORL1 and opioid 
receptors are unevenly distributed along the sequence of 
amino acids: they are particularly abundant in the puta- 
tive TMSs (67% identity), especially in the second (82%), 
third (82%) and seventh (80%) as well as in the cytoplas- 
mic loops and the first dozen of amino acids adjacent o 
TMS7 in the C-terminal segment (75% identity). In con- 
trast, hORL1 and opioid receptors differ profoundly in 
their N-terminal, second and third extracellular and C- 
terminal domains. Moreover, hORL1 contains two as- 
partate residues: D,,, in TMS3 and D,, in TMS2 which 
may represent key determinants for agonist binding and 
allosteric regulation thereof, respectively. Such two resi- 
dues are highly conserved among GPCRs for catechol- 
amines and other protonated amines (acetylcholine, opi- 
ates, . ..) and there is evidence that the one n TMS3 is the 
anionic subsite for the agonist [32] while the other (in 
TMS2) might support selective sensitivity of agonist 
binding to Na’ ions [33,34]. 
Pharmacological identification of hORL1 was first at- 
tempted on membranes from COS-7 cells transfected 
with pSVL: hORL1 as well as from CHO-Kl cells trans- 
fected with pRc/CMV : hORL1, using the following radi- 
olabeled ligands: the two potent, non-selective, ‘univer- 
sal’ opiate ligands, [3H]diprenorphine (antagonist) and 
[3H]etorphine (agonist), [1251]B-endorphin, the putative 
natural agonist of the ill-defined &-opioid receptor [35], 
12SI-labeled SS14 and SMS, somatostatin receptor ag- 
onists and o (non-PCP) receptor ligands: [3H]DTG and 
[3H]JO-1784. These ligands where chosen on the basis of 
sequence homology of hORL1, opioid and somatostatin 
receptors and of pharmacological homology between 
opioid receptors and the Q receptor whose prototypical 
ligand is the benzomorphan N-allylnormetazocine [36]. 
Actually, none of these ligands could be shown to specif- 
ically bind membranes of COS: and CHO:hORLl cells 
at concentrations up to 10 nM. In contrast, when COS 
cells were transfected with the rat /?,-adrenergic receptor 
cDNA (control transfection), they expressed, as ex- 
pected, high levels of high affinity binding for [1251]cy- 
anopindolol (not shown). It was therefore concluded that 
hORL1 is probably not a typical opioid, somatostatin or 
0 receptor. 
Next, a variety of unlabelled drugs was screened for 
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Fig. 2. Alignment of ORLl, opioid and somatostatin receptors. Alignment of the amino acid sequence of ORLl with those of the three rat opioid 
receptor types 0, p and IC (OPRD, OPRM and OPRK, respectively) and of the five rat somatostatin receptors. Similarities with the ORLl sequence 
are boxed. The putative membrane-spanning domains are numbered I to VII. The dendrogram represents sequence similarities between the receptors 
whose sequences are shown. It was constructed by using the Clustal software [44]. 
their ability to stimulate or inhibit adenylyl cyclase in 
CHO-Kl cells stably transfected with the pRc/ 
CMV: hORL1 construct. The choice of ade- 
nylyl cyclase was dictated by the facts that: (i) ORLl 
resembles most opioid receptors in domains that are 
thought to interact with G proteins; and (ii) opioid recep- 
tors have long been known to be (negatively) coupled 
with adenylyl cyclase [37,38]. The drugs, all tested first 
at the concentration of 10 PM, included nonselective 
(etorphine and ethylketocyclazocine), p-preferring (mor- 
phine, fentanyl, [Met’lenkephalin and [D-Ala’,Me- 
Phe4,Gly-ol’lenkephalin), &selective ([D-PeI?,D- 
Pen’lenkephalin) and K-selective (tifluadom, dynorphin 
A,_, and [D-Pro’ojdynorphin A,-,,) opioid agonists as 
well as the two opiate antagonists naloxone and 
diprenorphine. Also included in this test were the cr/PCP 
receptor agonist, phencyclidine, the Q (non-PCP) recep- 
tor ligands, pentazocine (also an opioid receptor agonist) 
and haloperidol, somatostatin- 14, ibogaine, an indole 
alkaloid that is being claimed as a ‘quick fix’ (Endabuse) 
for addiction [39] and F8Fa, an amidated octapeptide 
with anti-opioid activities [40]. If none of these elicited 
increase of intracellular levels of cyclic AMP, one, 
c:: ;c ‘J 
P 1 -- 5o 0.01 0.l 1 10 100 1 10 100 
etorphine , ymol/l diprenorphine,pmol/l 
Fig. 3. Forskolin-induced accumulation of CAMP in CHO-Kl cells 
stably transfected with a pRc/CMV: ORLl construct. (A) Inhibition by 
etorphine. Control cells were CHO-Kl cells transfected with the human 
cannabinoid receptor cDNA (BSOS) in the same expression vector. 
Etorphine produced up to 40% inibition with an I&, of about 0.7 PM 
in CHO:ORLl cells and was essentially inactive in control cells at 
concentrations up to 100 ,uM. Each value is the mean & S.D. of the 
values from 3 or 4 independent experiments. (B) Reversion by diprenor- 
phine of etorphine’s inhibitory action. Etorphine was used at the fixed 
concentration of 3 PM in the presence of increasing doses of diprenor- 
phine. Inhibition in the absence of diprenorphine was 28% relative to 
control (no etorphine). Each value is the mean + S.D. of a triplicate 
assay. 
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Fig. 4. Hybridocytochemical detection of ORLl-like RNA transcripts in the mouse brain. Autoradiograms were generated by hybridization with 
‘SS-labelled oligonucleotides complementary to mOP86,,, and mOP86,,,, in coronal sections of the mouse brain and spinal cord. The distribution 
is presented in rostra1 to caudal sections (A-C, E&H). D: hybridization with labeled probes and a loft-fold excess of cold probes. Abbreviations: AC, 
anterior commissure; AcC, core of accumbens; AcS, shell of accumbens; AO, anterior olfactory nucleus; Arc, arcuate nucleus; B, brain stem; BL, 
basolateral amygdala; C, cerebellum; CA, central amygdala; CAl-3, sectors l-3 of hippocampal Amman’s horn; CC, corpus calosum; Cg, cingulate 
cortex; Cl, claustrum; CP, caudate-putamen; DG, dentate gyrus; DH, dorsal horn of spinal cord; F, frontal cortex; FP, fronto-parietal cortex; IC, 
internal capsule; LS, lateral septum; MA, medial amygdala; MH, medial habenular nucleus; MP, medial preoptic area; PO, primary olfactory cortex; 
Th, thalamus; VH, ventral horn of spinal cord; VM, ventromedial nucleus. 
namely etorphine, was found to inhibit forskolin-stimu- 
lated production of CAMP in two independent clones of 
transfected CHO cells. Fig. 3A shows that etorphine’s 
inhibition of forskolin-elicited increase of CAMP was 
dose dependent (ED,, = 0.7 ,uM) and amounted to up 
to 40% of control (no drug added) values. In control 
cells, i.e. CHO cells stably transfected either with a 
human cannabinoid receptor cDNA [41] in pRc/CMV or 
with pSV2neo, 10 PM etorphine had no effect. Signifi- 
cantly enough, diprenorphine (Fig. 3B) and, however 
less potently so, naloxone (not shown) were found to 
antagonize the inhibitory action of etorphine in the 
CHO : hORL 1 cells. 
Finally, while attempting to identify the hORL1 recep- 
tor, we examined the CNS of the mouse for specific in 
situ hybridization with the two oligonucleotide 45-mers 
complementary to distinct regions of mouse genomic 
PCR product mOP86, the murine counterpart of hOPO1. 
Selected results are shown in Fig. 4. High levels of hy- 
bridization were observed in the septum (lateral, medial, 
septo-hippocampal nd septo-hypothalamic muclei), the 
horizontal and vertical limbs of the diagonal band of 
Broca, the hypothalamus (preoptic anterior and medial, 
arcuate, paraventricular, ventromedial nuclei), the sub- 
fornical organ, the hippocampus (Ammon’s horn CA3 
and other areas), the medial habenular nucleus, the me- 
dial amygdala, throughout the brainstem (including the 
periaqueductal gray matter) and in the dorsal as well as 
in the ventral horn of the spinal cord. Moderate hybrid- 
ization signals were seen in the olfactory nuclei, through- 
out the superficial and deep layers of the cerebral cortex 
(including the primary olfactory, cingulate, claustrum 
and fronto-parietal regions), the shell of the nucleus ac- 
cumbens, the islets of Calleja, the thalamus and the hip- 
pocampal dentate gyrus. Low levels of hybridization 
were visible in the caudate-putamen, the core of the nu- 
cleus accumbens and cerebellum. No signal was present 
in the white matter of the anterior commissure, corpus 
callosum and internal capsule. 
4. Discussion 
We report here the cloning of hOLR1, a new G pro- 
tein-coupled receptor which belongs to the newly charac- 
terized opioid receptor subfamily. Indeed, the closest rel- 
atives of hOLR1 are the three types of opioid receptor 
with whom it shares many structural traits, especially in 
the membrane-spanning and cytoplasmic domains. The 
high similarities within the latter, in particular the third 
cytoplasmic loop, suggest that hORL1 is capable of acti- 
vating the same G proteins as do opioid receptors: Gi to 
inhibit adenylyl cyclase [4], Gk to stimulate a K+ channel 
[6] and G, to inhibit a Ca2+ channel [5]. Accordingly, we 
have found that, in CHO cells transfected with a pRc/ 
CMV : hORL 1 construct, hORL1 mediates in- 
hibition of adenylyl cyclase by the ‘universal’ opiate ag- 
onist, etorphine. Moreover, this effect is abolished by 
diprenorphine, a ‘universal’ opiate antagonist of the 
same chemical family. In these cells, however, etorphine 
is far less potent (ICsO = 0.7 pmol/l) than in the NG 108- 
15 hybrid cell line in which, by acting on the o-opioid 
receptor, it inhibits the enzyme at concentrations in the 
range l-10 nmol/l [42]. The high concentration of these 
38 
ligands required here for biological activity, and the lack 
of activity of other opioid substances suggest that 
hORL1 is not a classical opioid receptor. The low po- 
tency of etorphine and diprenorphine can also be cor- 
related with the absence of detectable binding of up to 
10 nmol/l concentrations of the tritiated ligands in mem- 
branes from transfected COS cells. For comparison, 
[3H]diprenorphine and [3H]etorphine bind mammalian 
and amphibian [43] types of opioid receptors with &s in 
the range 0.1-l nmol/l. Thus, the detailed pharmacol- 
ogical profile of hORL1 will have to be determined, as 
well as the nature of its natural ligand which is not ex- 
pected to be one of the prototypical endogenous opioid 
peptides Q?-endorphin, enkephalin and dynorphin), since 
these were not active in our bioassay. 
We also report here that ORLl transcripts are dis- 
cretely yet widely expressed in the CNS of the mouse, 
suggesting that the ORLl receptor is potentially en- 
dowed with a variety of central functions. Schematically, 
these may include regulation of neuroendocrine secre- 
tion in the hypothalamo-pituitary axis, motricity in the 
ventral horn of the spinal cord, nociception in the central 
gray and dorsal horn of the spinal cord, instinctive be- 
haviors, emotions and possibly, learning and memory in 
the limbic areas. Hence the urgency of discovering the 
natural agonist(s) of this new receptor which, because it 
has been cloned out of a cDNA library from human 
brain stem, is also expressed in the human brain. 
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